

In the Specification:

Please amend the specification as shown:

Please delete Table 1 on page 5 and replace it with the following Table:

TABLE 1 – Antiviral Peptides

Peptide	SEQUENCE ID NUMBER	Sequence
EB	SEQ ID NO:1	NH ₂ - RRKKA VALLPAVLLALLAP-COOH
bEB	SEQ ID NO:2	b - RRKKA VALLPAVLLALLAP-COOH
EBPP	SEQ ID NO:3	NH ₂ - RRKKA VALLAVLLALLAPP-COOH
LALA	SEQ ID NO:4	NH ₂ - RRKKP A VLLALLA-COOH
bKLA	SEQ ID NO:5	b - K L A L K L A L K A A L K L A-amide
bKLAd _{11,12}	SEQ ID NO:6	b - K L A L K L A L K A A L K L A-amide
bHOM-9	SEQ ID NO:7	b - RQIKI WFPNRRMKWKK-9
bHOMd	SEQ ID NO:8	b - RQIKI WFPNRRMKWKK-amide
bHOMFF	SEQ ID NO:9	b - RQIKI F FPNRRMK F KK-amide
bTAT-9	SEQ ID NO:10	b - YGRKKRRQRRR-9
bTAT-9x	SEQ ID NO:11	b - YGRKKRRQRRR-9x
N ^{E13} – biotinyl transportan	SEQ ID NO:12	GWTLNSAGYLLGKINL K ALAALAKKIL b
VT5	SEQ ID NO:13	fluor-DPKGD P KGVTVTVTGTGKD P KD

Residues indicated in bold are positively charged residues

b = biotin-aminohexanoyl

d = peptide composed of all D amino acid residues

fluor = fluorescent label

-9 = PGYAGAVVNDL-COOH (SEQ ID NO: 31)

-9x = PGDVYANGLVA-COOH (SEQ ID NO: 32)

Please delete the paragraph on page 14, lines 25-29 and replace it with the following paragraph:

The charged amino-terminal R-R-K-K tetramer (**SEQ ID NO: 16**) was found to be useful for enhancing the solubility of the otherwise hydrophobic antiviral peptide EB, but does not have any important antiviral activity by itself. In the presence of serum, no antiviral activity was associated with the free R-R-K-K tetramer (SEQ ID NO:16) at concentrations as high as 200 μ M (Fig. 1A, (\blacktriangle)).